Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).

导出原文传递

翻译打印收藏纠错

作者： T,Bachelot ^[1] ; E,Ciruelos ^[2] ; A,Schneeweiss ^[3] ; F,Puglisi ^[4] ; T,Peretz-Yablonski ^[5] ; I,Bondarenko ^[6] ; S,Paluch-Shimon ^[7] ; A,Wardley ^[8] ; J-L,Merot ^[9] ; Y,du Toit ^[10] ; V,Easton ^[10] ; N,Lindegger ^[10] ; D,Miles ^[11] ; PERUSE investigators

作者单位： Medical Oncology Department, Centre Léon Bérard, Lyon, France. Electronic address: thomas.bachelot@lyon.unicancer.fr. ^[1] Medical Oncology Department Breast Care Unit, Hospital Universitario 12 de Octubre, Madrid, Spain. ^[2] Gynecologic Oncology Division, National Center for Tumor Diseases, University Hospital and German Cancer Research Center, Heidelberg, Germany. ^[3] IRCCS Centro di Riferimento Oncologico Aviano-National Cancer Institute, Aviano; Department of Medicine, University of Udine, Udine, Italy. ^[4] Sharett Institute of Oncology and Center for Malignant Breast Diseases, Hadassah Medical Organization, Jerusalem, Israel. ^[5] City Clinical Hospital No. 4, Dnipropetrovsk, Ukraine. ^[6] Breast Oncology Unit, Shaare Zedek Medical Centre, Jerusalem, Israel. ^[7] The NIHR Manchester Clinical Research Facility at the Christie NHS Foundation Trust, Manchester; Faculty of Biology Medicine & Health, Division of Cancer Sciences, School of Medical Sciences, University of Manchester, Manchester, UK. ^[8] Medical and Scientific Services, Oncology Therapeutic Unit, IQVIA, Saint Ouen, France. ^[9] Global Product Development Medical Affairs Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland. ^[10] Mount Vernon Cancer Centre, Middlesex, UK. ^[11]

关键词 HER2-positive dual HER2 blockade first line metastatic breast cancer paclitaxel pertuzumab